Biotech Shares Rip Following Collaboration Announcement For Monkeypox Research

A Scotland-based biotech company is finding a tremendous amount of success so far during Tuesday’s session after the company announced it entered into a research planning collaboration with Dr. Carlos Maluquer de Motes for the development of a treatment for Monkeypox.

Traders were quick to buy up shares of TC BioPharm (Holdings) plc (Nasdaq:TCBP) following the announcement, with shares of this micro cap quickly reaching up to $3.8799/share (+70.92%) at the early session high. This move could be indicative of this stock finally finding support for the first time in quite some time. 

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com’s content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

View the original article on AllPennyStocks.com

]]>